Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Multiple Sclerosis

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 168 articles:
HTML format
Text format



Single Articles


    October 2017
  1. TSIVGOULIS G, Papadimitropoulos GN, Katsanos AH, Zompola C, et al
    Teaching NeuroImages: Interferon-induced psoriasis flare in a multiple sclerosis case remits with dimethyl fumarate.
    Neurology. 2017;89:e188-e189.
    PubMed     Text format    


    September 2017
  2. KARCESKI S
    Multiple sclerosis, inflammation in the brain, and mood.
    Neurology. 2017;89:e169-e171.
    PubMed     Text format    


  3. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1429-1430.
    PubMed     Text format    


  4. SETHI NK
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis and Physician-assisted death in chronic neurologic diseases.
    Neurology. 2017;89:1429.
    PubMed     Text format    


  5. MASDEU JC
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1428.
    PubMed     Text format    


  6. THORMANN A, Sorensen PS, Koch-Henriksen N, Laursen B, et al
    Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.
    Neurology. 2017 Sep 20. pii: 10.1212/WNL.0000000000004508.
    PubMed     Text format     Abstract available


  7. MARRIE RA, Beck CA
    Preventing multiple sclerosis: To (take) vitamin D or not to (take) vitamin D?
    Neurology. 2017 Sep 13. pii: 10.1212/WNL.0000000000004506.
    PubMed     Text format    


  8. FILLI L, Zorner B, Killeen T, Linnebank M, et al
    Author response: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1200.
    PubMed     Text format    


  9. DAVIS FA
    Letter re: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1199.
    PubMed     Text format    


  10. COLES AJ, Cohen JA, Fox EJ, Giovannoni G, et al
    Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
    Neurology. 2017;89:1117-1126.
    PubMed     Text format     Abstract available


  11. HAVRDOVA E, Arnold DL, Cohen JA, Hartung HP, et al
    Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
    Neurology. 2017;89:1107-1116.
    PubMed     Text format     Abstract available


  12. LORSCHEIDER J, Jokubaitis VG, Spelman T, Izquierdo G, et al
    Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
    Neurology. 2017;89:1050-1059.
    PubMed     Text format     Abstract available


    August 2017
  13. LANGER-GOULD A, Wu J, Lucas R, Smith J, et al
    Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: A multiethnic study.
    Neurology. 2017 Aug 30. pii: 10.1212/WNL.0000000000004412.
    PubMed     Text format     Abstract available


  14. HENNES EM, Baumann M, Schanda K, Anlar B, et al
    Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.
    Neurology. 2017;89:900-908.
    PubMed     Text format     Abstract available


  15. ROSSI S, Studer V, Motta C, Polidoro S, et al
    Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004411.
    PubMed     Text format     Abstract available


  16. KOCH-HENRIKSEN N, Lauer K
    Dietary sodium intake: An etiologic dead end in multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004426.
    PubMed     Text format    


  17. CORTESE M, Yuan C, Chitnis T, Ascherio A, et al
    No association between dietary sodium intake and the risk of multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004417.
    PubMed     Text format     Abstract available


  18. WIENDL H, Bourdette D, Ciccarelli O
    Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?
    Neurology. 2017 Aug 23. pii: 10.1212/WNL.0000000000004381.
    PubMed     Text format    


  19. DE MEO E, Moiola L, Ghezzi A, Veggiotti P, et al
    MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004388.
    PubMed     Text format     Abstract available



  20. Escalation therapy for multiple sclerosis in Austria: Analysis of gender differences in the nationwide registry.
    Neurology. 2017;89:752.
    PubMed     Text format    


    July 2017
  21. NIELSEN NM, Munger KL, Stenager E, Ascherio A, et al
    Author response: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:411.
    PubMed     Text format    


  22. XIA Z, Cheng Q, Li J
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410-411.
    PubMed     Text format    


  23. ZARGHAMI A
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410.
    PubMed     Text format    


  24. MARANZANO J, Rudko DA, Nakamura K, Cook S, et al
    MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis.
    Neurology. 2017 Jul 19. pii: 10.1212/WNL.0000000000004227.
    PubMed     Text format     Abstract available


  25. HACOHEN Y, Mankad K, Chong WK, Barkhof F, et al
    Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Neurology. 2017;89:269-278.
    PubMed     Text format     Abstract available


  26. LANGER-GOULD A, Smith JB, Hellwig K, Gonzales E, et al
    Breastfeeding, ovulatory years, and risk of multiple sclerosis.
    Neurology. 2017 Jul 12. pii: 10.1212/WNL.0000000000004207.
    PubMed     Text format     Abstract available



  27. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017;89:215.
    PubMed     Text format    


  28. BURKILL S, Montgomery S, Hajiebrahimi M, Hillert J, et al
    Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012.
    Neurology. 2017 Jul 7. pii: 10.1212/WNL.0000000000004216.
    PubMed     Text format     Abstract available


    June 2017
  29. DE JONG HJI, Kingwell E, Shirani A, Cohen Tervaert JW, et al
    Evaluating the safety of beta-interferons in MS: A series of nested case-control studies.
    Neurology. 2017;88:2310-2320.
    PubMed     Text format     Abstract available


    May 2017
  30. BATISTA S, Alves C, d'Almeida OC, Afonso A, et al
    Disconnection as a mechanism for social cognition impairment in multiple sclerosis.
    Neurology. 2017 May 31. pii: 10.1212/WNL.0000000000004060.
    PubMed     Text format     Abstract available


  31. SOLOMON AJ, Weinshenker BG
    Author response: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067-2068.
    PubMed     Text format    


  32. DALLA COSTA G, Martinelli V, Comi G
    Letter re: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067.
    PubMed     Text format    


  33. ESHAGHI A, Ciccarelli O
    Author response: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed     Text format    


  34. AVASARALA J
    Letter re: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed     Text format    


  35. MEIJER KA, Eijlers AJC, Douw L, Uitdehaag BMJ, et al
    Increased connectivity of hub networks and cognitive impairment in multiple sclerosis.
    Neurology. 2017 May 3. pii: 10.1212/WNL.0000000000003982.
    PubMed     Text format     Abstract available


    April 2017
  36. SORMANI MP, Muraro PA, Schiavetti I, Signori A, et al
    Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017 Apr 28. pii: 10.1212/WNL.0000000000003987.
    PubMed     Text format     Abstract available


  37. GIANFRANCESCO MA, Stridh P, Rhead B, Shao X, et al
    Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS.
    Neurology. 2017;88:1623-1629.
    PubMed     Text format     Abstract available


    March 2017
  38. LANDI D, De Rossi N, Zagaglia S, Scarpazza C, et al
    No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
    Neurology. 2017;88:1144-1152.
    PubMed     Text format     Abstract available


  39. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017 Mar 15. pii: 10.1212/WNL.0000000000003831.
    PubMed     Text format     Abstract available


  40. ABSINTA M, Cortese IC, Vuolo L, Nair G, et al
    Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003820.
    PubMed     Text format     Abstract available


    February 2017
  41. NASH RA, Hutton GJ, Racke MK, Popat U, et al
    High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
    Neurology. 2017;88:842-852.
    PubMed     Text format     Abstract available


  42. KUHLE J, Nourbakhsh B, Grant D, Morant S, et al
    Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
    Neurology. 2017;88:826-831.
    PubMed     Text format     Abstract available


  43. SIDHOM Y, Maillart E, Tezenas du Montcel S, Kacem I, et al
    Fast multiple sclerosis progression in North Africans: Both genetics and environment matter.
    Neurology. 2017 Feb 24. pii: 10.1212/WNL.0000000000003762.
    PubMed     Text format     Abstract available


  44. MOWRY EM, McArthur JC
    PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
    Neurology. 2017 Feb 22. pii: 10.1212/WNL.0000000000003749.
    PubMed     Text format    


  45. EIJLERS AJ, Meijer KA, Wassenaar TM, Steenwijk MD, et al
    Increased default-mode network centrality in cognitively impaired multiple sclerosis patients.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003689.
    PubMed     Text format     Abstract available


  46. BARTON J, Hardy TA, Riminton S, Reddel SW, et al
    Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003694.
    PubMed     Text format    


  47. BODINI B, Calabresi PA
    From neurofilament research to multiple sclerosis clinical practice: Where do we stand?
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003676.
    PubMed     Text format    


  48. FILLI L, Zorner B, Kapitza S, Reuter K, et al
    Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003656.
    PubMed     Text format     Abstract available


  49. BENNETT SE
    Fampridine: Long-term benefits in walking in multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003677.
    PubMed     Text format    


    January 2017
  50. MAAROUF A, Audoin B, Pariollaud F, Gherib S, et al
    Increased total sodium concentration in gray matter better explains cognition than atrophy in MS.
    Neurology. 2017;88:289-295.
    PubMed     Text format     Abstract available


  51. BARGIELA D, Bianchi MT, Westover MB, Chibnik LB, et al
    Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis.
    Neurology. 2017 Jan 13. pii: 10.1212/WNL.0000000000003612.
    PubMed     Text format     Abstract available


  52. BUTTON J, Al-Louzi O, Lang A, Bhargava P, et al
    Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.
    Neurology. 2017 Jan 11. pii: 10.1212/WNL.0000000000003582.
    PubMed     Text format     Abstract available


    December 2016
  53. ROCCA MA, Battaglini M, Benedict RH, De Stefano N, et al
    Brain MRI atrophy quantification in MS: From methods to clinical application.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003542.
    PubMed     Text format     Abstract available


    November 2016
  54. NIELSEN NM, Munger KL, Koch-Henriksen N, Hougaard DM, et al
    Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2016 Nov 30. pii: 10.1212/WNL.0000000000003454.
    PubMed     Text format     Abstract available


  55. TENSER RB, Truini A, Cruccu G
    A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
    Neurology. 2016;87:2385-2386.
    PubMed     Text format    



  56. Pediatric multiple sclerosis: The 2015 Sydney Carter Award Lecture.
    Neurology. 2016;87:2284.
    PubMed     Text format    


  57. BEADNALL HN, Gill AJ, Riminton S, Barnett MH, et al
    Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003434.
    PubMed     Text format    



  58. Pediatric multiple sclerosis: Conventional first-line treatment and general management.
    Neurology. 2016;87:2068.
    PubMed     Text format    


  59. ESHAGHI A, Wottschel V, Cortese R, Calabrese M, et al
    Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2016 Nov 2. pii: 10.1212/WNL.0000000000003395.
    PubMed     Text format     Abstract available


    October 2016
  60. BOURDETTE D
    Rituximab for treating multiple sclerosis: Off-label but on target.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003345.
    PubMed     Text format    


  61. SALZER J, Svenningsson R, Alping P, Novakova L, et al
    Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003331.
    PubMed     Text format     Abstract available


  62. GIOVANNONI G, Cohen JA, Coles AJ, Hartung HP, et al
    Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
    Neurology. 2016 Oct 12. pii: 10.1212/WNL.0000000000003319.
    PubMed     Text format     Abstract available


    September 2016
  63. DORANS KS, Massa J, Chitnis T, Ascherio A, et al
    Physical activity and the incidence of multiple sclerosis.
    Neurology. 2016 Sep 28. pii: 10.1212/WNL.0000000000003260.
    PubMed     Text format     Abstract available


  64. KANTOR D, Sotirchos ES, Calabresi PA
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:1424.
    PubMed     Text format    


  65. COTTER J, Firth J, Enzinger C, Kontopantelis E, et al
    Social cognition in multiple sclerosis: A systematic review and meta-analysis.
    Neurology. 2016 Sep 21. pii: 10.1212/WNL.0000000000003236.
    PubMed     Text format     Abstract available


  66. KELLY DM, Kelleher EM, O'Shea A, Sweeney B, et al
    Teaching Video NeuroImages: Primary writing tremor: Lessons from a patient with multiple sclerosis.
    Neurology. 2016;87:e131.
    PubMed     Text format    


  67. BOVE R, White CC, Fitzgerald KC, Chitnis T, et al
    Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis.
    Neurology. 2016 Sep 7. pii: 10.1212/WNL.0000000000003176.
    PubMed     Text format     Abstract available


  68. VOSKUHL R, Patti F
    Hormone replacement in menopausal women with multiple sclerosis: Looking back, thinking forward.
    Neurology. 2016 Sep 7. pii: 10.1212/WNL.0000000000003189.
    PubMed     Text format    


  69. ARNOLD DL, Fisher E, Brinar VV, Cohen JA, et al
    Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003169.
    PubMed     Text format     Abstract available


    August 2016
  70. SOLOMON AJ, Bourdette DN, Cross AH, Applebee A, et al
    The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2016 Aug 31. pii: 10.1212/WNL.0000000000003152.
    PubMed     Text format     Abstract available


  71. GHEZZI A, Amato MP, Makhani N, Shreiner T, et al
    Pediatric multiple sclerosis: Conventional first-line treatment and general management.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  72. BANWELL B, Arnold DL, Tillema JM, Rocca MA, et al
    MRI in the evaluation of pediatric multiple sclerosis.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  73. AMATO MP, Krupp LB, Charvet LE, Penner I, et al
    Pediatric multiple sclerosis: Cognition and mood.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  74. WALDMAN A, Ness J, Pohl D, Simone IL, et al
    Pediatric multiple sclerosis: Clinical features and outcome.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  75. HINTZEN RQ, Dale RC, Neuteboom RF, Mar S, et al
    Pediatric acquired CNS demyelinating syndromes: Features associated with multiple sclerosis.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  76. KRUPP LB, Rintell D, Charvet LE, Milazzo M, et al
    Pediatric multiple sclerosis: Perspectives from adolescents and their families.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  77. CHITNIS T, Ghezzi A, Bajer-Kornek B, Boyko A, et al
    Pediatric multiple sclerosis: Escalation and emerging treatments.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  78. BANWELL B
    Pediatric multiple sclerosis: The 2015 Sydney Carter Award Lecture.
    Neurology. 2016;87:822-6.
    PubMed     Text format    


  79. KHALIL M, Salzer J
    CSF neurofilament light: A universal risk biomarker in multiple sclerosis?
    Neurology. 2016 Aug 12. pii: 10.1212/WNL.0000000000003107.
    PubMed     Text format    



  80. Journal Club: Effect of comorbidity on mortality in multiple sclerosis.
    Neurology. 2016;87:646.
    PubMed     Text format    


  81. JONES DE, Sutliff MH, Halper J, Armstrong MJ, et al
    Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2016;87:646.
    PubMed     Text format    


    July 2016
  82. PURCHIARONI F, Salvetti M, Buscarinu MC, Annibale B, et al
    Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003045.
    PubMed     Text format    


  83. BENOIT A, Durand-Dubief F, Amato MP, Portaccio E, et al
    History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003036.
    PubMed     Text format     Abstract available


  84. GILMORE W, Airas L
    Successive pregnancies in multiple sclerosis.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003039.
    PubMed     Text format    


  85. GOLAN D, Miller A, Sotirchos ES, Bhargava P, et al
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:446.
    PubMed     Text format    


  86. AVASARALA J, Sotirchos ES, Bhargava P, Calabresi PA, et al
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:445-6.
    PubMed     Text format    


  87. PREZIOSA P, Comi G, Filippi M
    Optic neuritis in multiple sclerosis: Looking from a patient's eyes.
    Neurology. 2016;87:338-9.
    PubMed     Text format    


  88. MILLER AE, Pelletier D
    Multiple sclerosis: Rapid diagnosis or right diagnosis?
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002994.
    PubMed     Text format    


  89. BROWNLEE WJ, Swanton JK, Miszkiel KA, Miller DH, et al
    Should the symptomatic region be included in dissemination in space in MRI criteria for MS?
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002975.
    PubMed     Text format     Abstract available


    June 2016
  90. WANG G, Marrie RA, Salter AR, Fox R, et al
    Health insurance affects the use of disease-modifying therapy in multiple sclerosis.
    Neurology. 2016 Jun 29. pii: 10.1212/WNL.0000000000002887.
    PubMed     Text format     Abstract available


  91. LEHMANN-HORN K, Penkert H, Grein P, Leppmeier U, et al
    PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
    Neurology. 2016 Jun 24. pii: 10.1212/WNL.0000000000002900.
    PubMed     Text format    


  92. DE FLON P, Gunnarsson M, Laurell K, Soderstrom L, et al
    Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
    Neurology. 2016 Jun 17. pii: 10.1212/WNL.0000000000002832.
    PubMed     Text format     Abstract available


    May 2016
  93. KARAMYAN A, Sellner J
    Journal Club: Effect of comorbidity on mortality in multiple sclerosis.
    Neurology. 2016;86:e228-30.
    PubMed     Text format    


  94. SENA A, Capela C, Ferret-Sena V, Munger KL, et al
    No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
    Neurology. 2016;86:2026.
    PubMed     Text format    


  95. BUTTMANN M, Seuffert L, Mader U, Toyka KV, et al
    Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.
    Neurology. 2016 May 11. pii: 10.1212/WNL.0000000000002745.
    PubMed     Text format     Abstract available


  96. TRUINI A, Prosperini L, Calistri V, Fiorelli M, et al
    A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
    Neurology. 2016 May 4. pii: 10.1212/WNL.0000000000002720.
    PubMed     Text format     Abstract available


    April 2016
  97. SUMOWSKI JF, Rocca MA, Leavitt VM, Meani A, et al
    Brain reserve against physical disability progression over 5 years in multiple sclerosis.
    Neurology. 2016 Apr 27. pii: 10.1212/WNL.0000000000002702.
    PubMed     Text format     Abstract available


  98. DE LOTT LB, Burke JF, Kerber KA, Skolarus LE, et al
    Medicare Part D payments for neurologist-prescribed drugs.
    Neurology. 2016;86:1491-8.
    PubMed     Text format     Abstract available



  99. Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
    Neurology. 2016;86:1465.
    PubMed     Text format    


  100. MCDONNELL GV, Bennett A, Rae-Grant A, Bever C, et al
    Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
    Neurology. 2016;86:1361.
    PubMed     Text format    


  101. BENNETT A, Rae-Grant A, Bever C
    Author Response.
    Neurology. 2016;86:1361.
    PubMed     Text format    


    March 2016
  102. HODEL J, Darchis C, Outteryck O, Verclytte S, et al
    Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Neurology. 2016 Mar 23. pii: 10.1212/WNL.0000000000002586.
    PubMed     Text format     Abstract available


  103. GRANT WB, Riise T
    Multiple sclerosis: A lifestyle disease?
    Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002487.
    PubMed     Text format    


  104. BERRIGAN LI, Fisk JD, Patten SB, Tremlett H, et al
    Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.
    Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002564.
    PubMed     Text format     Abstract available


  105. MARRIE RA, Patten SB, Tremlett H, Wolfson C, et al
    Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study.
    Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002481.
    PubMed     Text format     Abstract available


  106. O'CONNOR P, Comi G, Freedman MS, Miller AE, et al
    Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
    Neurology. 2016;86:920-30.
    PubMed     Text format     Abstract available


  107. ZHANG T, Tremlett H, Leung S, Zhu F, et al
    Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
    Neurology. 2016 Mar 4. pii: 10.1212/WNL.0000000000002543.
    PubMed     Text format     Abstract available


    February 2016
  108. BARBIN L, Rousseau C, Jousset N, Casey R, et al
    Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
    Neurology. 2016;86:771-8.
    PubMed     Text format     Abstract available


  109. MARRIE RA, Miller A, Sormani MP, Thompson A, et al
    The challenge of comorbidity in clinical trials for multiple sclerosis.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002471.
    PubMed     Text format     Abstract available


  110. DILOKTHORNSAKUL P, Valuck RJ, Nair KV, Corboy JR, et al
    Multiple sclerosis prevalence in the United States commercially insured population.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002469.
    PubMed     Text format     Abstract available


  111. MARRIE RA, Miller A, Sormani MP, Thompson A, et al
    Recommendations for observational studies of comorbidity in multiple sclerosis.
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002474.
    PubMed     Text format     Abstract available


  112. CORTESE I, Ohayon J, Fenton K, Lee CC, et al
    Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
    Neurology. 2016 Feb 3. pii: 10.1212/WNL.0000000000002417.
    PubMed     Text format     Abstract available


  113. HAN C, Huang J, Waxman SG
    Sodium channel Nav1.8: Emerging links to human disease.
    Neurology. 2016;86:473-83.
    PubMed     Text format     Abstract available


    January 2016
  114. SHEIKH Z, Jain S, Hillen M
    Acute retinal necrosis in multiple sclerosis: A neuroimmunologic challenge!
    Neurology. 2016 Jan 29. pii: 10.1212/WNL.0000000000002450.
    PubMed     Text format    


  115. BOURRE B, Gueudry J, Lefaucheur R, Borden A, et al
    Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
    Neurology. 2016;86:312-3.
    PubMed     Text format    


  116. LINCOLN MR, Schneider R, Hohol M
    Clinical Reasoning: A 34-year-old man with headache, diplopia, and hemiparesis.
    Neurology. 2016;86:e24-8.
    PubMed     Text format    


  117. CHITNIS T, Ness J, Krupp L, Waubant E, et al
    Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.
    Neurology. 2016;86:245-52.
    PubMed     Text format     Abstract available


  118. BODINI B, Chard D, Altmann DR, Tozer D, et al
    White and gray matter damage in primary progressive MS: The chicken or the egg?
    Neurology. 2016;86:170-6.
    PubMed     Text format     Abstract available


  119. WAXMAN SG, Kantarci O
    The cerebellar channelopathy of multiple sclerosis.
    Neurology. 2016 Jan 6. pii: 10.1212/WNL.0000000000002338.
    PubMed     Text format    


  120. ROOSTAEI T, Sadaghiani S, Park MT, Mashhadi R, et al
    Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis.
    Neurology. 2016 Jan 6. pii: 10.1212/WNL.0000000000002326.
    PubMed     Text format     Abstract available


    December 2015
  121. SOTIRCHOS ES, Bhargava P, Eckstein C, Van Haren K, et al
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002316.
    PubMed     Text format     Abstract available


  122. LIEBERMAN LA, Zeng W, Singh C, Wang W, et al
    CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002314.
    PubMed     Text format     Abstract available


  123. MARRIE RA, Fisk JD, Tremlett H, Wolfson C, et al
    Differences in the burden of psychiatric comorbidity in MS vs the general population.
    Neurology. 2015;85:1972-9.
    PubMed     Text format     Abstract available


    November 2015
  124. HASELKORN JK, Hughes C, Rae-Grant A, Henson LJ, et al
    Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2015;85:1896-903.
    PubMed     Text format     Abstract available



  125. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
    Neurology. 2015;85:1728.
    PubMed     Text format    


  126. TISCHNER JR, Hartung DM, Bourdette DN, Whitham RH, et al
    The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
    Neurology. 2015;85:1727-8.
    PubMed     Text format    


  127. RITTENHOUSE BE
    The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
    Neurology. 2015;85:1727-8.
    PubMed     Text format    


  128. HARTUNG DM, Bourdette DN, Ahmed S, Whitham RH, et al
    Author response.
    Neurology. 2015;85:1728.
    PubMed     Text format    


  129. RITTENHOUSE BE
    The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
    Neurology. 2015;85:1727-8.
    PubMed     Text format    


  130. HARTUNG DM, Bourdette DN, Whitham RH
    Author response.
    Neurology. 2015;85:1727.
    PubMed     Text format    


  131. DE STEFANO N, Stromillo ML, Giorgio A, Battaglini M, et al
    Long-term assessment of no evidence of disease activity in relapsing-remitting MS.
    Neurology. 2015;85:1722-3.
    PubMed     Text format    


  132. DEBS R, Maillart E, Fahed R, Papeix C, et al
    Extensive brain demyelinating lesions under natalizumab: The role of anti-natalizumab antibodies.
    Neurology. 2015;85:1630-2.
    PubMed     Text format    


    October 2015
  133. LOUAPRE C, Govindarajan ST, Gianni C, Langkammer C, et al
    Beyond focal cortical lesions in MS: An in vivo quantitative and spatial imaging study at 7T.
    Neurology. 2015 Oct 14. pii: 10.1212/WNL.0000000000002106.
    PubMed     Text format     Abstract available



  134. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.
    Neurology. 2015;85:1355.
    PubMed     Text format    


  135. MUNGER KL, Fitzgerald KC, Freedman MS, Hartung HP, et al
    No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
    Neurology. 2015 Oct 9. pii: 10.1212/WNL.0000000000002099.
    PubMed     Text format     Abstract available


  136. LAURSEN JH, Sondergaard HB, Sorensen PS, Sellebjerg F, et al
    Association between age at onset of multiple sclerosis and vitamin D level-related factors.
    Neurology. 2015 Oct 7. pii: 10.1212/WNL.0000000000002075.
    PubMed     Text format     Abstract available


  137. BOVE R, Malik MT, Diaz-Cruz C, Chua A, et al
    The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS.
    Neurology. 2015;85:1209-13.
    PubMed     Text format     Abstract available


  138. LUCAS RM, Banwell B
    Do prenatal sex hormones modulate MS risk?
    Neurology. 2015;85:1193-4.
    PubMed     Text format    


    September 2015
  139. LABINER DM
    William A. Sibley, MD (1925-2015).
    Neurology. 2015;85:1016.
    PubMed     Text format    



  140. Meningeal inflammation in multiple sclerosis: The key to the origin of cortical lesions?
    Neurology. 2015;85:1010.
    PubMed     Text format    


  141. RAE-GRANT A, Bennett A, Sanders AE, Phipps M, et al
    Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
    Neurology. 2015 Sep 2. pii: 10.1212/WNL.0000000000001965.
    PubMed     Text format    


    August 2015
  142. PARDINI M, Yaldizli O, Sethi V, Muhlert N, et al
    Motor network efficiency and disability in multiple sclerosis.
    Neurology. 2015 Aug 28. pii: 10.1212/WNL.0000000000001970.
    PubMed     Text format     Abstract available


  143. SORMANI MP, Evangelou N
    New imaging language skills required in MS.
    Neurology. 2015 Aug 28. pii: 10.1212/WNL.0000000000001978.
    PubMed     Text format    


  144. HUANG D
    Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod.
    Neurology. 2015 Aug 19. pii: 10.1212/WNL.0000000000001929.
    PubMed     Text format    


  145. RINGELSTEIN M, Albrecht P, Kleffner I, Buhn B, et al
    Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography.
    Neurology. 2015;85:610-8.
    PubMed     Text format     Abstract available


  146. ROCCA MA, Filippi M, Deiva K
    Promoting physical activity to control multiple sclerosis from childhood.
    Neurology. 2015 Aug 12. pii: 10.1212/WNL.0000000000001941.
    PubMed     Text format    


  147. GROVER SA, Aubert-Broche B, Fetco D, Collins DL, et al
    Lower physical activity is associated with higher disease burden in pediatric multiple sclerosis.
    Neurology. 2015 Aug 12. pii: 10.1212/WNL.0000000000001939.
    PubMed     Text format     Abstract available


    July 2015
  148. HACOHEN Y, Zuberi S, Vincent A, Crow YJ, et al
    Neuromyelitis optica in a child with Aicardi-Goutieres syndrome.
    Neurology. 2015;85:381-3.
    PubMed     Text format    


  149. NOVOTNA M, Paz Soldan MM, Abou Zeid N, Kale N, et al
    Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.
    Neurology. 2015 Jul 24. pii: 10.1212/WNL.0000000000001856.
    PubMed     Text format     Abstract available


  150. WINGERCHUK DM, Banwell B, Bennett JL, Cabre P, et al
    International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
    Neurology. 2015;85:177-89.
    PubMed     Text format     Abstract available


  151. KISTER I, Paul F
    Pushing the boundaries of neuromyelitis optica: does antibody make the disease?
    Neurology. 2015;85:118-9.
    PubMed     Text format    


  152. KAPPOS L, Radue EW, Comi G, Montalban X, et al
    Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
    Neurology. 2015;85:29-39.
    PubMed     Text format     Abstract available


  153. TRANAH GJ, Santaniello A, Caillier SJ, D'Alfonso S, et al
    Mitochondrial DNA sequence variation in multiple sclerosis.
    Neurology. 2015 Jul 1. pii: 10.1212/WNL.0000000000001744.
    PubMed     Text format     Abstract available


    June 2015
  154. DAAMS M, Steenwijk MD, Wattjes MP, Geurts JJ, et al
    Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis.
    Neurology. 2015 Jun 26. pii: 10.1212/WNL.0000000000001756.
    PubMed     Text format     Abstract available


  155. ROVIRA A, Wiggermann V, Rauscher A
    Trajectories of subcortical iron accumulation in MS.
    Neurology. 2015;84:2388-9.
    PubMed     Text format    


  156. PFENDER N, Jelcic I, Linnebank M, Schwarz U, et al
    Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.
    Neurology. 2015;84:2377-8.
    PubMed     Text format    


    May 2015
  157. MARRIE RA, Elliott L, Marriott J, Cossoy M, et al
    Effect of comorbidity on mortality in multiple sclerosis.
    Neurology. 2015 May 27. pii: 10.1212/WNL.0000000000001718.
    PubMed     Text format     Abstract available


  158. BROWN MG
    Cost of disease-modifying therapies for multiple sclerosis.
    Neurology. 2015;84:e181-5.
    PubMed     Text format    


  159. GILBERT GJ
    A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.
    Neurology. 2015;84:2201.
    PubMed     Text format    


  160. VAN TASSEL SH, Gupta MP, Orlin A, Nealon NM, et al
    Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
    Neurology. 2015;84:2198-9.
    PubMed     Text format    


  161. MURRAY TJ, Brown MG
    Escalating MS drug costs in the US: Puzzling, troubling, and suspicious.
    Neurology. 2015;84:2105-6.
    PubMed     Text format    


  162. KHALIL M, Langkammer C, Pichler A, Pinter D, et al
    Dynamics of brain iron levels in multiple sclerosis: A longitudinal 3T MRI study.
    Neurology. 2015 May 15. pii: 10.1212/WNL.0000000000001679.
    PubMed     Text format     Abstract available


    April 2015
  163. WEINSHENKER BG, Barron G, Behne JM, Bennett JL, et al
    Challenges and opportunities in designing clinical trials for neuromyelitis optica.
    Neurology. 2015;84:1805-15.
    PubMed     Text format     Abstract available


  164. LIU Y, Wang J, Daams M, Weiler F, et al
    Differential patterns of spinal cord and brain atrophy in NMO and MS.
    Neurology. 2015;84:1465-72.
    PubMed     Text format     Abstract available


    March 2015
  165. MURARO PA
    Andiamo! Moving forward with autologous hematopoietic transplantation for highly active MS.
    Neurology. 2015;84:968-9.
    PubMed     Text format    


  166. LUBLIN FD
    Author response.
    Neurology. 2015;84:963.
    PubMed     Text format    


    February 2015
  167. KIM HJ, Paul F, Lana-Peixoto MA, Tenembaum S, et al
    MRI characteristics of neuromyelitis optica spectrum disorder: An international update.
    Neurology. 2015 Feb 18. pii: 10.1212/WNL.0000000000001367.
    PubMed     Text format     Abstract available


  168. MILLER DH, Fox RJ, Phillips JT, Hutchinson M, et al
    Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
    Neurology. 2015 Feb 13. pii: 10.1212/WNL.0000000000001360.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: